Curus™ is a polymolecular product of natural origin being developed by Natural MA Inc.
Research Milestones
Antiviral Activity- in vitro
- Human Rhinovirus 16: University of Calgary
- Infectious Salmon Anemia Virus: University of PEI and University of Maine
- Herpes Simplex Virus I: University of Maine
Antiviral Activity - In vivo
- White Spot Syndrome Virus: The Center for Aquaculture Technologies
- Potato Leaf Roll Virus: Ag research company
Animal Trials
- Arthritic dogs: 50% of animals showed pain progression (untreated) vs. 12.5% (treated).
- Veal Calves High Risk (for disease) : 50% increase of animals without respiratory issues. 50% decrease of antibiotic treatments.
- Horses: The benefits to older horses with impaired mobility has been attested by numerous testimonials as reported on equine15.com/testimonials
- Shrimp: White Spot Syndrome Virus: 50% reduction in mortality. Study ongoing.
Toxicity
- In vitro: Curus™ was tested on cardiac cells expressing hERG channels (University of Calgary) and no adverse effects were reported. Moreover, the low toxic profile was also observed in many different cell lines.
- In Vivo: A comprehensive study was performed in mice where a dose of 200 mg/kg for 1 week was well tolerated with no toxic effects. Curus™ was tested in cattle (90 days), pigs (15 days), horses, dogs (56 days), mice (7 days) and shrimp (16 days) without any noticeable toxic effects.
